New BioNTech production facility in Germany

In the statement made by BioNTech, it was indicated that 40 million euros will be invested in the complete installation.

In the statement, it was stated that most of the plasmid DNA components needed for mRNA-based medicines for cancer and infectious diseases will be produced at this facility.

PROMISE OF THE PRIME MINISTER

Visiting the facility in Marburg, some 90 kilometers north of Frankfurt, German Chancellor Olaf Scholz stated that he welcomes BioNTech’s investment.

Scholz said: “Medical biotechnology is the key technology of the 21st century. The COVID-19 pandemic has demonstrated Germany’s ability to be a place of pharmaceutical innovation and production. Germany and Europe are becoming more flexible by creating local value chains. This BioNTech investment is very good news. You can see and feel that this is truly the future.” he used the phrase.

Stressing that more needs to be done to help Germany’s biotech companies open those factories faster, develop new treatments and bring their products to market, Scholz vowed to seek to improve the legal framework for healthcare companies, including providing a better access to data for research purposes. . .

BioNTech, co-founder of Turkish scientist Uğur Şahin, bought the Marburg facility from Swiss-based pharmaceutical company Novartis in 2020. (BRITISH AUTOMOBILE CLUB)